Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06029244 · ClinicalTrials.gov registry record · NA
Eyecontrol coMmunication Platform for dEliRium manaGemEnt in Intensive Care Units (EMERGE)
A NA study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 160
- Enrollment target
NCT06029244 is a NA study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 160 participants.
The verdict
NCT06029244, a NA study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
Study Summary
The purpose of this research is to investigate whether addition of the EyeControl-Pro platform as an adjunct to standard guideline-based intensive care unit management of critically ill patients is effective in reducing delirium incidence and severity.
Interventions
- OTHER Control
- DEVICE EyeControl-Pro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2024-02-25 |
| Est. Completion | 2025-11-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06029244
The ClinicalTrials.gov registry entry for NCT06029244 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT06029244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06029244 about?
NCT06029244 is a clinical study titled "Eyecontrol coMmunication Platform for dEliRium manaGemEnt in Intensive Care Units (EMERGE)". The purpose of this research is to investigate whether addition of the EyeControl-Pro platform as an adjunct to standard guideline-based intensive care unit management of critically ill patients is effective in reducing delirium incidence and severity.
What is the current status of trial NCT06029244?
This trial is currently completed. It is a NA study. The enrollment target is 160 participants. The study started on 2024-02-25. Estimated completion is 2025-11-18.
What interventions are being tested in trial NCT06029244?
The interventions under investigation include: Control (OTHER), EyeControl-Pro (DEVICE).
Who is sponsoring clinical trial NCT06029244?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.